People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mira1a Therapeutics, Inc. | — | Pharmaceuticals | Series A | $7.1M | $7.7M | 2021 |
Paul Rivard, ESQ at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Rivard, ESQ on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jude Uzonwanne | 1 | 3 |
| Josh Silverman | 1 | 2 |
| Brad Kroenig | 1 | 1 |
| James McNulty, CPA | 1 | 1 |
| Hugh McColl III | 1 | 1 |
| Talhia Tuck, JD | 1 | 1 |
| Dave Vorhoff | 1 | 1 |
| Adam Kaplin, MD, PhD | 1 | 1 |
| Chris Chapman, MD | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.